Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
THE APEX TIMES
THE APEX TIMES
The approvals extend Moderna’s push beyond a single product cycle, indicating how the company plans to pair next-generation COVID formulations with an mRNA influenza entry.
THE APEX TIMES
In a widely shared personal finance anecdote, commentator Suze Orman used a Moderna (MRNA) trading spike to underscore how fast market moves can change individual outcomes, after one investor said she sold following relationship pressure just before the shares jumped sharply.
THE APEX TIMES
The biotech said it plans a private placement of convertible senior notes and a “capped call” transaction meant to reduce potential dilution from any future conversion.
THE APEX TIMES
In a recent Mad Money segment, Cramer focused on Moderna’s mRNA platform as a caller recounted a sharp move in the stock and asked whether to sell or hold after a phase 3 cancer trial update.
THE APEX TIMES
A Yahoo Finance wrap-up of second-quarter results put Moderna’s performance in context with other healthcare therapeutics stocks, underscoring how investors weigh growth, pipeline progress, and near-term fundamentals.
THE APEX TIMES
The companies said their Phase 3 trial of intismeran plus Merck’s Keytruda met its stated goals in a study of 1,137 patients.
THE APEX TIMES
The biotechnology company said it is raising additional capital to support oncology work, shortly after regulators cleared updated COVID-19 vaccines for the next phase of use.
THE APEX TIMES
Shares of BioNTech SE fell sharply after news of an mRNA trial failure, reversing a recent momentum rally across companies developing mRNA-based therapies. The move is drawing fresh attention to how investors are differentiating outcomes across the group, with Moderna often acting as the benchmark given its larger late-stage pipeline.
